Truist Securities Reiterates Buy Rating, $718 Price Target on Regeneron Pharma (REGN) Despite Biogen's (BIIB) Byooviz Launch
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $718.00 price target on Regeneron Pharma (NASDAQ: REGN), following Biogen's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
